Company intelligence / Profile preview

Novadiol Australia

Shawnee, Kansas, United States

Ownership: Private
Development stage: Other

Overview

Novadiol is a biopharmaceutical company focused on developing therapies for kidney diseases, primarily secondary hyperparathyroidism (SHPT) in patients with stage 3 and 4 chronic kidney disease. Its lead candidate, Dendocrin, is a next-generation formulation designed to deliver a reliable increase in 25-hydroxyvitamin D (25D) levels. The company utilizes the 505(b)(2) regulatory pathway, which allows for accelerated development by leveraging existing safety and toxicity data for known molecules.

Therapeutic areas: EndocrinologyNephrology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Novadiol Australia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novadiol Australia.

Explore the full profile